TrialMuscle & nerve2026

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.

Jerry R Mendell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.